Model Medicines completed a two-day Non-Deal Roadshow hosted by Mizuho Securities in New York City, engaging more than a dozen institutional investors across crossover public-private funds, early-stage venture groups, and global long-only asset managers. The meetings provided an opportunity to introduce Model Medicines’ pipeline, platform strategy, and execution roadmap to a broader public-market audience. Feedback from the roadshow affirmed investor interest in the company’s scientific approach, the credibility of its therapeutic programs, and the maturity of its development strategy as Model Medicines advances toward clinical entry.

The roadshow was hosted by Salim Syed, Managing Director at Mizuho Securities, whose biotechnology research team is known for its coverage of public healthcare and biotech companies, clinical pipelines, and market trends.